SA
GNNSF logo
Genscript Biotech Corporation(GNNSF)
Last print unknown agoAbout this dataData status
$3.78▲0.00 (0.00%)Stale · unknown old

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 25.4 · elevated volatility

Overview →

Genscript Biotech Corporation (GNNSF)

R&D to Revenue

7.42%

Fiscal year · Period ending:

GNNSF logo

GNNSF R&D to Revenue

Latest reported7.42%
GNNSF FY R&D/Revenue (10.09% → 7.42%)
High-resolution chart · PNG

What is r&d to revenue?

R&D spending as percentage of revenue.

GNNSF r&d to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.

Genscript Biotech Corporation R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
7.4236%
9.048%
9.4021%
62.3457%
73.1287%
67.3925%
68.0517%
32.0652%
11.8278%
8.2512%
8.1987%
7.985%
10.0892%

Frequently asked questions: GNNSF r&d to revenue

What is Genscript Biotech Corporation (GNNSF)'s current r&d to revenue?

Genscript Biotech Corporation (GNNSF)'s latest reported r&d to revenue (Fiscal year) is 7.42% as of Dec 31, 2025. R&D spending as percentage of revenue.

How much historical r&d to revenue data is available for GNNSF?

Stock Alarm Pro provides 13 dated annual fiscal periods observations for Genscript Biotech Corporation (GNNSF)'s r&d to revenue, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare GNNSF's r&d to revenue to peers or set an alert?

You can open GNNSF's r&d to revenue in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on GNNSF delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.